Page 117 - Read Online

Miller et al. J Cancer Metastasis Treat 2019;5:68 I http://dx.doi.org/10.20517/2394-4722.2019.001 Page 11 of 11

cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 2014;15:656-66.
74. Fisher G. A phase III study of xilonix in refractory colorectal cancer patients with weight loss. J Clin Oncol 2015;33:685-5.
75. Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a
randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2017;18:192-201.
76. Paspaliaris V, Langan B, DeAndrea R, Wood J, Tsouvelekas A, et al. Phase I/II study of IP-1510 a novel interleukin-1 receptor antagonist in
the management of cancer-related cachexia. J Cachexia Sarcopenia Muscle 2011;2:261.
77. Bayliss T, Smith J, Schuster M, Dragnev K, Rigas J. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin
Biol Ther 2011;11:1663-8.
78. Coss C, Clinton S, Phelps M. Cachectic cancer patients: immune to check-point inhibitor therapy? Clin Cancer Res. 2018;24:5787-9.
79. Kollipara R, Fughhi I, Batus M, Basu S, Borgia J, et al. Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal
antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival. J Clin Oncol
2019;37:e20710.
80. Multani M, Tarhoni I, Fughhi I, Basu S, Batus M, et al. Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor
therapy in advanced-stage non-small cell lung cancer patients. J Clin Oncol 2019;37:e14061.
81. Dolan RD, Laird BJA, Horgan PG, McMillan DC. The prognostic value of the systemic inflammatory response in randomised clinical trials
in cancer: a systematic review. Crit Rev Oncol Hematol 2018;132:130-7.
82. Roxburgh CSD, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 2014;110:1409-12.
83. Ter Veer E, van Rijssen L, Besselink M. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for
systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60.